Search Results

There are 8741 results for: content related to: Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing–remitting multiple sclerosis: a prospective, non-randomized pilot study

  1. Therapeutic interference with leukocyte recirculation in multiple sclerosis

    European Journal of Neurology

    Volume 22, Issue 3, March 2015, Pages: 434–442, F. Sellebjerg and P. S. Sørensen

    Version of Record online : 13 JAN 2015, DOI: 10.1111/ene.12668

  2. You have full text access to this OnlineOpen article
    Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

    European Journal of Neurology

    Volume 21, Issue 3, March 2014, Pages: 377–e20, M. S. Freedman

    Version of Record online : 15 NOV 2013, DOI: 10.1111/ene.12299

  3. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years

    European Journal of Neurology

    Volume 23, Issue 6, June 2016, Pages: 1101–1109, R. Zivadinov, D. Hojnacki, N. Bergsland, C. Kennedy, J. Hagemeier, R. Melia, D. P. Ramasamy, J. Durfee, E. Carl, M. G. Dwyer and B. Weinstock-Guttman

    Version of Record online : 21 MAR 2016, DOI: 10.1111/ene.12992

  4. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 87–94, S. Rossi, C. Motta, V. Studer, V. De Chiara, F. Barbieri, F. Monteleone, A. Fornasiero, G. Coarelli, G. Bernardi, G. Cutter, O. Stüve, M. Salvetti and D. Centonze

    Version of Record online : 28 JUN 2012, DOI: 10.1111/j.1468-1331.2012.03794.x

  5. You have full text access to this OnlineOpen article
    Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

    European Journal of Neurology

    Volume 22, Issue 3, March 2015, Pages: 570–577, N. Voloshyna, E. Havrdová, M. Hutchinson, T. Nehrych, X. You, S. Belachew, C. Hotermans and D. Paes

    Version of Record online : 15 DEC 2014, DOI: 10.1111/ene.12618

  6. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients

    European Journal of Neurology

    Volume 23, Issue 1, January 2016, Pages: 182–189, M. I. Domínguez-Mozo, M. García-Montojo, A. Arias-Leal, Á. García-Martínez, J. L. Santiago, I. Casanova, V. Galán, R. Arroyo, M. Fernández-Arquero and R. Alvarez-Lafuente

    Version of Record online : 25 OCT 2015, DOI: 10.1111/ene.12834

  7. High cumulative JC virus seroconversion rate during long-term use of natalizumab

    European Journal of Neurology

    Volume 23, Issue 6, June 2016, Pages: 1079–1085, A. Vennegoor, J. A. van Rossum, C. Leurs, M. P. Wattjes, T. Rispens, J. L. A. N. Murk, B. M. J. Uitdehaag and J. Killestein

    Version of Record online : 27 MAR 2016, DOI: 10.1111/ene.12988

  8. You have full text access to this OnlineOpen article
    Disease-modifying treatments for multiple sclerosis – a review of approved medications

    European Journal of Neurology

    Volume 23, Issue S1, January 2016, Pages: 18–27, Ø. Torkildsen, K.-M. Myhr and L. Bø

    Version of Record online : 13 NOV 2015, DOI: 10.1111/ene.12883

  9. Antibody biomarkers in CNS demyelinating diseases – a long and winding road

    European Journal of Neurology

    Volume 22, Issue 8, August 2015, Pages: 1162–1168, T. Berger and M. Reindl

    Version of Record online : 24 MAY 2015, DOI: 10.1111/ene.12759

  10. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation

    European Journal of Neurology

    Volume 22, Issue 3, March 2015, Pages: 585–587, M. Capobianco, A. di Sapio, M. Malentacchi, S. Malucchi, M. Matta, F. Sperli and A. Bertolotto

    Version of Record online : 3 JUL 2014, DOI: 10.1111/ene.12487

  11. You have free access to this content
    A basic overview of multiple sclerosis immunopathology

    European Journal of Neurology

    Volume 22, Issue S2, October 2015, Pages: 3–13, N. Grigoriadis and V. van Pesch

    Version of Record online : 16 SEP 2015, DOI: 10.1111/ene.12798

  12. You have free access to this content
    Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis

    European Journal of Neurology

    Volume 24, Issue 1, January 2017, Pages: 112–121, J. Mellergård, A. Tisell, I. Blystad, A. Grönqvist, K. Blennow, B. Olsson, C. Dahle, M. Vrethem, P. Lundberg and J. Ernerudh

    Version of Record online : 4 OCT 2016, DOI: 10.1111/ene.13162

  13. Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis

    European Journal of Neurology

    Volume 20, Issue 7, July 2013, Pages: 1032–1042, R. A. Grove, S. Shackelford, S. Sopper, S. Pirruccello, J. Horrigan, E. Havrdova, M. Gold and O. Graff

    Version of Record online : 18 FEB 2013, DOI: 10.1111/ene.12097

  14. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

    European Journal of Neurology

    Volume 24, Issue 9, September 2017, Pages: 1196–1199, Z. L. E. van Kempen, C. E. Leurs, A. de Vries, A. Vennegoor, T. Rispens, M. P. Wattjes and J. Killestein

    Version of Record online : 14 JUL 2017, DOI: 10.1111/ene.13355

  15. You have free access to this content
    Overview of the management of relapsing−remitting multiple sclerosis and practical recommendations

    European Journal of Neurology

    Volume 22, Issue S2, October 2015, Pages: 14–21, P. Gallo and B. Van Wijmeersch

    Version of Record online : 16 SEP 2015, DOI: 10.1111/ene.12799

  16. Recent advances in neurology 2013–2014

    European Journal of Neurology

    Volume 21, Issue 12, December 2014, Pages: 1425–1434, A. H. V. Schapira

    Version of Record online : 13 NOV 2014, DOI: 10.1111/ene.12619

  17. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

    European Journal of Neurology

    Volume 21, Issue 1, January 2014, Pages: 40–48, O. Outteryck, J.C. Ongagna, B. Brochet, L. Rumbach, C. Lebrun-Frenay, M. Debouverie, H. Zéphir, J.C. Ouallet, E. Berger, M. Cohen, S. Pittion, D. Laplaud, S. Wiertlewski, P. Cabre, J. Pelletier, A. Rico, G. Defer, N. Derache, W. Camu, E. Thouvenot, T. Moreau, A. Fromont, A. Tourbah, P. Labauge, G. Castelnovo, P. Clavelou, O. Casez, P. Hautecoeur, C. Papeix, C. Lubetzki, B. Fontaine, N. Couturier, N. Bohossian, M. Clanet, P. Vermersch, J. de Sèze, D. Brassat and on behalf of the BIONAT network, and CFSEP

    Version of Record online : 12 JUN 2013, DOI: 10.1111/ene.12204

  18. You have free access to this content
    An overview of pregnancy-related issues in patients with multiple sclerosis

    European Journal of Neurology

    Volume 22, Issue S2, October 2015, Pages: 34–39, C. Pozzilli and M. Pugliatti

    Version of Record online : 16 SEP 2015, DOI: 10.1111/ene.12797

  19. You have free access to this content
    Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 5–15, J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli and W. H. Oertel

    Version of Record online : 22 DEC 2012, DOI: 10.1111/j.1468-1331.2012.03866.x

  20. Natalizumab for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald and John WD McDonald

    Published Online : 24 JAN 2007, DOI: 10.1002/14651858.CD006097.pub2